13 results on '"James G Hakim"'
Search Results
2. Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052.
- Author
-
Philip J Palumbo, Ethan A Wilson, Estelle Piwowar-Manning, Marybeth McCauley, Theresa Gamble, Newton Kumwenda, Joseph Makhema, Nagalingeswaran Kumarasamy, Suwat Chariyalertsak, James G Hakim, Mina C Hosseinipour, Marineide G Melo, Sheela V Godbole, Jose H Pilotto, Beatriz Grinsztejn, Ravindre Panchia, Ying Q Chen, Myron S Cohen, Susan H Eshleman, and Jessica M Fogel
- Subjects
Medicine ,Science - Abstract
Higher HIV diversity has been associated with virologic outcomes in children on antiretroviral treatment (ART). We examined the association of HIV diversity with virologic outcomes in adults from the HPTN 052 trial who initiated ART at CD4 cell counts of 350-550 cells/mm3. A high resolution melting (HRM) assay was used to analyze baseline (pre-treatment) HIV diversity in six regions in the HIV genome (two in gag, one in pol, and three in env) from 95 participants who failed ART. We analyzed the association of HIV diversity in each genomic region with baseline (pre-treatment) factors and three clinical outcomes: time to virologic suppression after ART initiation, time to ART failure, and emergence of HIV drug resistance at ART failure. After correcting for multiple comparisons, we did not find any association of baseline HIV diversity with demographic, laboratory, or clinical characteristics. For the 18 analyses performed for clinical outcomes evaluated, there was only one significant association: higher baseline HIV diversity in one of the three HIV env regions was associated with longer time to ART failure (p = 0.008). The HRM diversity assay may be useful in future studies exploring the relationship between HIV diversity and clinical outcomes in individuals with HIV infection.
- Published
- 2017
- Full Text
- View/download PDF
3. Adult Hematology and Clinical Chemistry Laboratory Reference Ranges in a Zimbabwean Population.
- Author
-
Wadzanai P Samaneka, Gibson Mandozana, Willard Tinago, Nehemiah Nhando, Nyaradzo M Mgodi, Mutsawashe F Bwakura-Dangarembizi, Marshall W Munjoma, Zvenyika A R Gomo, Zvavahera M Chirenje, and James G Hakim
- Subjects
Medicine ,Science - Abstract
Laboratory reference ranges used for clinical care and clinical trials in various laboratories in Zimbabwe were derived from textbooks and research studies conducted more than ten years ago. Periodic verification of these ranges is essential to track changes over time. The purpose of this study was to establish hematology and chemistry laboratory reference ranges using more rigorous methods.A community-based cross-sectional study was carried out in Harare, Chitungwiza, and Mutoko. A multistage sampling technique was used. Samples were transported from the field for analysis at the ISO15189 certified University of Zimbabwe-University of California San Francisco Central Research Laboratory. Hematology and clinical chemistry reference ranges lower and upper reference limits were estimated at the 2.5th and 97.5th percentiles respectively.A total of 769 adults (54% males) aged 18 to 55 years were included in the analysis. Median age was 28 [IQR: 23-35] years. Males had significantly higher red cell counts, hemoglobin, hematocrit, and mean corpuscular hemoglobin compared to females. Females had higher white cell counts, platelets, absolute neutrophil counts, and absolute lymphocyte counts compared to males. There were no gender differences in eosinophils, monocytes, and absolute basophil count. Males had significantly higher levels of urea, sodium, potassium, calcium, creatinine, amylase, total protein, albumin and liver enzymes levels compared to females. Females had higher cholesterol and lipase compared with males. There are notable differences in the white cell counts, neutrophils, cholesterol, and creatinine kinase when compared with the currently used reference ranges.Data from this study provides new country specific reference ranges which should be immediately adopted for routine clinical care and accurate monitoring of adverse events in research studies.
- Published
- 2016
- Full Text
- View/download PDF
4. C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.
- Author
-
Mark W Tenforde, Nikhil Gupte, David W Dowdy, David M Asmuth, Ashwin Balagopal, Richard B Pollard, Patcharaphan Sugandhavesa, Javier R Lama, Sandy Pillay, Sandra W Cardoso, Jyoti Pawar, Breno Santos, Cynthia Riviere, Noluthando Mwelase, Cecilia Kanyama, Johnstone Kumwenda, James G Hakim, Nagalingeswaran Kumarasamy, Robert Bollinger, Richard D Semba, Thomas B Campbell, Amita Gupta, and ACTG PEARLS and NWCS 319 Study Group
- Subjects
Medicine ,Science - Abstract
OBJECTIVE:The association between pre-antiretroviral (ART) inflammation and immune activation and risk for incident tuberculosis (TB) after ART initiation among adults is uncertain. DESIGN:Nested case-control study (n = 332) within ACTG PEARLS trial of three ART regimens among 1571 HIV-infected, treatment-naïve adults in 9 countries. We compared cases (participants with incident TB diagnosed by 96 weeks) to a random sample of controls (participants who did not develop TB, stratified by country and treatment arm). METHODS:We measured pre-ART C-reactive protein (CRP), EndoCab IgM, ferritin, interferon gamma (IFN-γ), interleukin 6 (IL-6), interferon gamma-inducible protein 10 (IP-10), lipopolysaccharide (LPS), soluble CD14 (sCD14), tumor necrosis factor alpha (TNF-α), and CD4/DR+/38+ and CD8/DR+/38+ T cells. Markers were defined according to established cutoff definitions when available, 75th percentile of measured values when not, and detectable versus undetectable for LPS. Using logistic regression, we measured associations between biomarkers and incident TB, adjusting for age, sex, study site, treatment arm, baseline CD4 and log10 viral load. We assessed the discriminatory value of biomarkers using receiver operating characteristic (ROC) analysis. RESULTS:Seventy-seven persons (4.9%) developed incident TB during follow-up. Elevated baseline CRP (aOR 3.25, 95% CI: 1.55-6.81) and IP-10 (aOR 1.89, 95% CI: 1.05-3.39), detectable plasma LPS (aOR 2.39, 95% CI: 1.13-5.06), and the established TB risk factors anemia and hypoalbuminemia were independently associated with incident TB. In ROC analysis, CRP, albumin, and LPS improved discrimination only modestly for TB risk when added to baseline routine patient characteristics including CD4 count, body mass index, and prior TB. CONCLUSION:Incident TB occurs commonly after ART initiation. Although associated with higher post-ART TB risk, baseline CRP, IP-10, and LPS add limited value to routine patient characteristics in discriminating who develops active TB. Besides determining ideal cutoffs for these biomarkers, additional biomarkers should be sought that predict TB disease in ART initiators.
- Published
- 2015
- Full Text
- View/download PDF
5. Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.
- Author
-
Sujal M Parikh, Ekwaro A Obuku, Sarah A Walker, Aggrey S Semeere, Brandon J Auerbach, James G Hakim, Harriet Mayanja-Kizza, Peter N Mugyenyi, Robert A Salata, Cissy M Kityo, and DART Trial Team
- Subjects
Medicine ,Science - Abstract
OBJECTIVE:Clinical and immunological data about HIV in older adults from low and middle income countries is scarce. We aimed to describe differences between younger and older adults with HIV starting antiretroviral therapy in two low-income African countries. METHODS: SETTING:HIV clinics in Uganda and Zimbabwe. DESIGN:Secondary exploratory cross-sectional analysis of the DART randomized controlled trial. OUTCOME MEASURES:Clinical and laboratory characteristics were compared between adults aged 18-49 years (younger) and ≥ 50 years (older), using two exploratory multivariable logistic regression models, one with HIV viral load (measured in a subset pre-ART) and one without. RESULTS:A total of 3316 eligible participants enrolled in DART were available for analysis; 219 (7%) were ≥ 50 years and 1160 (35%) were male. Across the two adjusted regression models, older adults had significantly higher systolic blood pressure, lower creatinine clearance and were consistently less likely to be females compared to younger adults with HIV. Paradoxically, the models separately suggested that older adults had statistically significant (but not clinically important) higher CD4+ cell counts and higher plasma HIV-1 viral copies at initiation. Crude associations between older age and higher baseline hemoglobin, body mass index, diastolic blood pressure and lower WHO clinical stage were not sustained in the adjusted analysis. CONCLUSIONS:Our study found clinical and immunological differences between younger and older adults, in a cohort of Africans starting antiretroviral therapy. Further investigations should explore how these differences could be used to ensure equity in service delivery and affect outcomes of antiretroviral therapy.
- Published
- 2013
- Full Text
- View/download PDF
6. Antiretroviral Therapy for the Prevention of HIV-1 Transmission
- Author
-
Myron S, Cohen, Ying Q, Chen, Marybeth, McCauley, Theresa, Gamble, Mina C, Hosseinipour, Nagalingeswaran, Kumarasamy, James G, Hakim, Johnstone, Kumwenda, Beatriz, Grinsztejn, Jose H S, Pilotto, Sheela V, Godbole, Suwat, Chariyalertsak, Breno R, Santos, Kenneth H, Mayer, Irving F, Hoffman, Susan H, Eshleman, Estelle, Piwowar-Manning, Leslie, Cottle, Xinyi C, Zhang, Joseph, Makhema, Lisa A, Mills, Ravindre, Panchia, Sharlaa, Faesen, Joseph, Eron, Joel, Gallant, Diane, Havlir, Susan, Swindells, Vanessa, Elharrar, David, Burns, Taha E, Taha, Karin, Nielsen-Saines, David D, Celentano, Max, Essex, Sarah E, Hudelson, Andrew D, Redd, Thomas R, Fleming, and Robert, Bollinger
- Subjects
Male ,0301 basic medicine ,HPTN 052 ,HIV Infections ,Kaplan-Meier Estimate ,Medical and Health Sciences ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,HIV Seropositivity ,030212 general & internal medicine ,Young adult ,Transmission (medicine) ,Infectious ,virus diseases ,General Medicine ,Middle Aged ,Intention to Treat Analysis ,HPTN 052 Study Team ,Infectious Diseases ,Sexual Partners ,Anti-Retroviral Agents ,Serodiscordant ,HIV/AIDS ,Female ,Infection ,Adult ,Risk ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Young Adult ,03 medical and health sciences ,Disease Transmission ,Acquired immunodeficiency syndrome (AIDS) ,Clinical Research ,General & Internal Medicine ,Internal medicine ,Disease Transmission, Infectious ,medicine ,Humans ,Intention-to-treat analysis ,business.industry ,Prevention ,Interim analysis ,medicine.disease ,030112 virology ,Surgery ,Good Health and Well Being ,HIV-1 ,business ,Follow-Up Studies - Abstract
BackgroundAn interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission.MethodsWe randomly assigned 1763 index participants to receive either early or delayed ART. In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the delayed-ART group, 877 participants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illness) developed. The primary study end point was the diagnosis of genetically linked HIV-1 infection in the previously HIV-1-negative partner in an intention-to-treat analysis.ResultsIndex participants were followed for 10,031 person-years; partners were followed for 8509 person-years. Among partners, 78 HIV-1 infections were observed during the trial (annual incidence, 0.9%; 95% confidence interval [CI], 0.7 to 1.1). Viral-linkage status was determined for 72 (92%) of the partner infections. Of these infections, 46 were linked (3 in the early-ART group and 43 in the delayed-ART group; incidence, 0.5%; 95% CI, 0.4 to 0.7) and 26 were unlinked (14 in the early-ART group and 12 in the delayed-ART group; incidence, 0.3%; 95% CI, 0.2 to 0.4). Early ART was associated with a 93% lower risk of linked partner infection than was delayed ART (hazard ratio, 0.07; 95% CI, 0.02 to 0.22). No linked infections were observed when HIV-1 infection was stably suppressed by ART in the index participant.ConclusionsThe early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners. (Funded by the National Institute of Allergy and Infectious Diseases; HPTN 052 ClinicalTrials.gov number, NCT00074581 .).
- Published
- 2016
7. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
- Author
-
James G, Hakim, Jennifer, Thompson, Cissy, Kityo, Anne, Hoppe, Andrew, Kambugu, Joep J, van Oosterhout, Abbas, Lugemwa, Abraham, Siika, Raymond, Mwebaze, Aggrey, Mweemba, George, Abongomera, Margaret J, Thomason, Philippa, Easterbrook, Peter, Mugyenyi, A Sarah, Walker, Nicholas I, Paton, and J, Villacian
- Subjects
Adult ,Male ,Ritonavir ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Anti-HIV Agents ,HIV Infections ,Middle Aged ,Viral Load ,Lopinavir ,Young Adult ,Treatment Outcome ,Antiretroviral Therapy, Highly Active ,Raltegravir Potassium ,Humans ,Reverse Transcriptase Inhibitors ,Female ,Child ,Africa South of the Sahara ,Aged ,Follow-Up Studies - Abstract
Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings.We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787.Between April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that resulted in treatment modification.Protease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-limited settings.European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO.
- Published
- 2017
8. The magnitude of loss to follow-up of HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum of care: a systematic review and meta-analysis
- Author
-
Euphemia L, Sibanda, Ian V D, Weller, James G, Hakim, and Frances M, Cowan
- Subjects
loss to follow-up ,retention ,prevention of mother-to-child HIV transmission programs ,Epidemiology and Social ,Infant, Newborn ,review ,Infant ,HIV Infections ,Continuity of Patient Care ,Infectious Disease Transmission, Vertical ,meta-analysis ,HIV-exposed infants ,Pregnancy ,systematic ,Humans ,Female ,Lost to Follow-Up - Abstract
Introduction: Although prevention of mother-to-child HIV transmission (PMTCT) programs are widely implemented, many children do not benefit from them because of loss to follow-up (LTFU). We conducted a systematic review to determine the magnitude of infant/baby LTFU along the PMTCT cascade. Methods: Eligible publications reported infant LTFU outcomes from standard care PMTCT programs (not intervention studies) at any stage of the cascade. Literature searches were conducted in Medline, Embase, Web of Knowledge, CINAHL Plus, and Maternity and Infant Care. Extracted data included setting, methods of follow-up, PMTCT regimens, and proportion and timing of LTFU. For programs in sub-Saharan Africa, random-effects meta-analysis was done using Stata v10. Because of heterogeneity, predictive intervals (PrIs; approximate 95% confidence intervals of a future study based on extent of observed heterogeneity) were computed. Results: A total of 826 papers were identified; 25 publications were eligible. Studies were published from 2001 to 2012 and were mostly from sub-Saharan Africa (three were from India, one from UK and one from Ireland). There was extensive heterogeneity in findings. Eight studies reported on LTFU of pregnant HIV-positive women between antenatal care (ANC) registration and delivery, which ranged from 10.9 to 68.1%, pooled proportion 49.08% [95% confidence interval (CI) 39.6–60.9%], and PrI 22.0–100%. Fourteen studies reported LTFU of infants within 3 months of delivery, range 4.8–75%, pooled proportion 33.9% (27.6–41.5), and PrI 15.4–74.2. Children were also lost after HIV testing; this was reported in five studies, pooled estimate 45.5% (35.9–57.6), PrI 18.7–100%. Programs that actively tracked defaulters had better retention outcomes. Conclusion: There is unacceptable infant LTFU from PMTCT programs. Countries should incorporate defaulter-tracking as standard to improve retention.
- Published
- 2013
9. Prevention of HIV-1 infection with early antiretroviral therapy
- Author
-
Myron S, Cohen, Ying Q, Chen, Marybeth, McCauley, Theresa, Gamble, Mina C, Hosseinipour, Nagalingeswaran, Kumarasamy, James G, Hakim, Johnstone, Kumwenda, Beatriz, Grinsztejn, Jose H S, Pilotto, Sheela V, Godbole, Sanjay, Mehendale, Suwat, Chariyalertsak, Breno R, Santos, Kenneth H, Mayer, Irving F, Hoffman, Susan H, Eshleman, Estelle, Piwowar-Manning, Lei, Wang, Joseph, Makhema, Lisa A, Mills, Guy, de Bruyn, Ian, Sanne, Joseph, Eron, Joel, Gallant, Diane, Havlir, Susan, Swindells, Heather, Ribaudo, Vanessa, Elharrar, David, Burns, Taha E, Taha, Karin, Nielsen-Saines, David, Celentano, Max, Essex, Thomas R, Fleming, and Robert, Bollinger
- Subjects
HPTN 052 ,Adult ,Male ,Adolescent ,viruses ,HIV Infections ,Kaplan-Meier Estimate ,Pre-exposure prophylaxis ,Young Adult ,Pharmacotherapy ,HIV Seropositivity ,CAPRISA 004 ,Disease Transmission, Infectious ,Medicine ,Humans ,Spouses ,Proportional Hazards Models ,Transmission (medicine) ,business.industry ,General Medicine ,Treatment as prevention ,Virology ,Sexual Partners ,Treatment Outcome ,Viral replication ,Anti-Retroviral Agents ,Serodiscordant ,Immunology ,Disease Progression ,HIV-1 ,Drug Therapy, Combination ,Female ,business - Abstract
Background: Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. Methods: In nine countries, we enrolled 1763 couples in which one partner was HIV-1–positive and the other was HIV-1–negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1–infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1–related symptoms (delayed therapy). The primary prevention end point was linked HIV-1 transmission in HIV-1–negative partners. The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. Results: As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the earlytherapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P
- Published
- 2011
10. HIV prevention in southern Africa: why we must reassess our strategies?
- Author
-
Leolin, Katsidzira and James G, Hakim
- Subjects
Adult ,Male ,Acquired Immunodeficiency Syndrome ,Adolescent ,Anti-HIV Agents ,Adenine ,Organophosphonates ,HIV Infections ,Middle Aged ,Condoms ,Young Adult ,Circumcision, Male ,HIV Seropositivity ,Humans ,Female ,Interdisciplinary Communication ,Preventive Medicine ,Condoms, Female ,Tenofovir ,Risk Reduction Behavior - Abstract
Southern Africa continues to shoulder a disproportionate burden of the HIV epidemic with the number of new infections outstripping treatment initiation two- to threefold. Current prevention strategies have had a limited impact on the trajectory of the epidemic so far. The history of HIV prevention research is dominated by failed approaches, but recent developments have provided reason for hope. These include the successful male circumcision outcomes in trials in South Africa, Kenya and Uganda, the recent protective outcome of a tenofovir vaginal gel trial in South Africa and the proof that pre-exposure prophylaxis with oral combination tenofovir/emtricitabine can work in men. The latter positive outcome has however been shattered by the early closure of FEM-PrEP for futility. The challenge now is on how to best integrate emerging prevention methods with established strategies, recognising that some of the older methods have never been scaled up to saturation level.
- Published
- 2011
11. Unethical Study of the Natural History of Cryptococcal Meningitis in 1997
- Author
-
Robert S. Heyderman, Innocent T. Gangaidzo, James G. Hakim, Jens Mielke, Albert Taziwa, Praise Musvaire, Valerie J. Robertson, and Peter R. Mason
- Subjects
Microbiology (medical) ,Infectious Diseases - Published
- 1999
12. 'Well, not me, but other women do not register because...'- Barriers to seeking antenatal care in the context of prevention of mother-to-child transmission of HIV among Zimbabwean women: a mixed-methods study
- Author
-
Euphemia L. Sibanda, Sarah Bernays, Ian V. D. Weller, James G. Hakim, and Frances M. Cowan
- Subjects
Antenatal care ,PMTCT ,Qualitative study ,User fees ,HIV testing ,Gynecology and obstetrics ,RG1-991 - Abstract
Abstract Background While barriers to uptake of antenatal care (ANC) among pregnant women have been explored, much less is known about how integrating prevention of mother-to-child transmission (PMTCT) programmes within ANC services affects uptake. We explored barriers to uptake of integrated ANC services in a poor Zimbabwean community. Methods A cross-sectional survey was conducted among post-natal women at Mbare Clinic, Harare, between September 2010 and February 2011. Collected data included participant characteristics and ANC uptake. Logistic regression was conducted to determine factors associated with ANC registration. In-depth interviews were held with the first 21 survey participants who either did not register or registered after twenty-four weeks gestation to explore barriers. Interviews were analysed thematically. Results Two hundred and ninety-nine participants (mean age 26.1 years) were surveyed. They came from ultra-poor households, with mean household income of US$181. Only 229 (76.6%) had registered for ANC, at a mean gestation of 29.5 weeks. In multivariable analysis, household income was positively associated with ANC registration, odds ratio (OR) for a $10-increase in household income 1.02 (95% confidence interval, CI, 1.0–1.04), as was education which interacted with having planned the pregnancy (OR for planned pregnancy with completed ordinary level education 3.27 (95%CI 1.55–6.70). Divorced women were less likely to register than married women, OR 0.20 (95%CI 0.07–0.58). In the qualitative study, barriers to either ANC or PMTCT services limited uptake of integrated services. Women understood the importance of integrated services for PMTCT purposes and theirs and the babies’ health and appeared unable to admit to barriers which they deemed “stupid/irresponsible”, namely fear of HIV testing and disrespectful treatment by nurses. They represented these commonly recurring barriers as challenges that “other women” faced. The major proffered personal barrier was unaffordability of user fees, which was sometimes compounded by unsupportive husbands who were the breadwinners. Conclusion Women who delayed/did not register were aware of the importance of ANC and PMTCT but were either unable to afford or afraid to register. Addressing the identified challenges will not only be important for integrated PMTCT/ANC services but will also provide a model for dealing with challenges as countries scale up ‘treat all’ approaches.
- Published
- 2018
- Full Text
- View/download PDF
13. Role of Faculty Development Programs in Medical Education at the University of Zimbabwe College of Health Sciences, Zimbabwe
- Author
-
Antony Matsika, Kusum Nathoo, Margaret Borok, Thokozile Mashaah, Felix Madya, Susan Connors, Thomas Campbell, and James G. Hakim
- Subjects
Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Background: Major challenges are being experienced in medical education in sub-Saharan African Universities. These include emigration of faculty, infrequent curriculum review, inadequate training in medical education, poor investments in infrastructure and lack of faculty development programs. The USA government committed funding to improve the quality of medical education and research capacity in sub-Saharan Africa through the Medical Education Partnership Initiative (MEPI). Objectives: This article describes the implementation of faculty development at the University of Zimbabwe College of Health Sciences (UZCHS), a recipient of a MEPI award. Methods: Data sources included annual surveys and reports of UZCHS MEPI activities, exit evaluation reports of faculty development workshops; results of a survey conducted in 2015 at the end of the MEPI grant. Questionnaires were developed based on the MEPI Zimbabwe evaluation plan and logic model. Surveys were administered to faculty members, postgraduate and undergraduate students. Qualitative data was collected through in-depth key informer interviews of stakeholder. Findings: Different faculty development activities were implemented such as workshops, exchange visits, visiting professors program, advanced leadership training and curriculum development. The implementation of the activities brought positive developments to the college as confirmed by faculty and students. The majority of faculty interviewed (96%) confirmed that faculty development programs were very helpful in enhancing their expertise and skills. A similar number, i.e. 96%, also reported satisfaction with the training. Conclusions: We have described how the implementation of faculty development programs at the UZCHS contributed to the improvement of medical education at the College. The short term and long-term benefits of faculty development have been analyzed. Various forms of faculty development programs were described. Limitations of this analysis were the inability to collect data on students’ performance and the demonstration of changes in teaching performance.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.